Targeting the dentate nucleus with deep brain stimulation was safe and feasible for promoting post-stroke rehabilitation in a first-in-man study. A principal investigator shares next steps.
Several new technologies improve chances of hitting the sweet spot of symptom control with few side effects in deep brain stimulation (DBS) for movement disorders. The director of our DBS program reviews the essentials.
A $2.5 million NIH grant is supporting Cleveland Clinic preclinical studies of deep brain stimulation to treat motor and cognitive deficits after traumatic brain injury. The research extends our pioneering work on DBS for post-stroke rehabilitation.
Only about 10% of candidates for surgical intervention for movement disorders end up undergoing surgery. Our latest podcast discusses new approaches that may increase that percentage.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
The new deep brain stimulation system for epilepsy seems best suited to patients whose seizures are hard to localize or restrict to just a couple brain regions. We share insights as one of the initial U.S. treating sites.
The new director of our DBS program looks ahead to emerging applications for DBS and advancements in related technology, from directional leads to closed-loop stimulation.
It took over six years, 20+ visits, participation in two clinical drug trials and more to convince this physician patient the time was right to try deep brain stimulation. We share caregiving lessons learned along the way.
The Director of our Center for Neurological Restoration explains this designation from the Parkinson’s Foundation, from the application process through the benefits for patient care and research.
The first-in-human study of deep brain stimulation (DBS) for stroke recovery also features the first combined use of transcranial magnetic stimulation with cerebellar DBS in humans. Here’s why that matters.
The team conducting the first-in-human clinical trial of deep brain stimulation for stroke recovery garnered $2.5M to continue parallel preclinical studies of the underlying mechanisms.